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Abstract
Background: Tyrosine kinases are attractive targets for pancreatic cancer therapy because several are over-expressed,
including PDGFRa/b, FAK, Src and Lyn. A critical role of mast cells in the development of pancreatic cancer has also been
reported. Masitinib is a tyrosine kinase inhibitor that selectively targets c-Kit, PDGFRa/b, Lyn, and to a lesser extent the FAK
pathway, without inhibiting kinases of known toxicities. Masitinib is particularly efficient in controlling the proliferation,
differentiation and degranulation of mast cells. This study evaluates the therapeutic potential of masitinib in pancreatic
cancer, as a single agent and in combination with gemcitabine.
Methodology/Findings: Proof-of-concept studies were performed in vitro on human pancreatic tumour cell lines and then
in vivo using a mouse model of human pancreatic cancer. Molecular mechanisms were investigated via gene expression
profiling. Masitinib as a single agent had no significant antiproliferative activity while the masitinib/gemcitabine
combination showed synergy in vitro on proliferation of gemcitabine-refractory cell lines Mia Paca2 and Panc1, and to a
lesser extent in vivo on Mia Paca2 cell tumour growth. Specifically, masitinib at 10 mM strongly sensitised Mia Paca2 cells to
gemcitabine (.400-fold reduction in IC50); and moderately sensitised Panc1 cells (10-fold reduction). Transcriptional analysis
identified the Wnt/b-catenin signalling pathway as down-regulated in the cell lines resensitised by the masitinib/
gemcitabine combination.
Conclusions: These data establish proof-of-concept that masitinib can sensitise gemcitabine-refractory pancreatic cancer
cell lines and warrant further in vivo investigation. Indeed, such an effect has been recently observed in a phase 2 clinical
study of patients with pancreatic cancer who received a masitinib/gemcitabine combination.
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Introduction
Pancreatic cancer is an aggressive malignancy that is frequently
diagnosed at an advanced stage with poor prognosis. In
approximately 15–20% of cases the tumour is resectable, but only
20% of these patients will survive 5 years [1]. For locally advanced,
unresectable and metastatic disease, chemo- and radiotherapy
provide relatively little benefit. Gemcitabine (Gemzar, Lilly
France), a nucleoside analogue of cytidine, improves symptoms
and survival as compared to 5-FU-based chemotherapy, and is
now established as the standard systemic treatment in pancreatic
cancer [2]. However, the efficacy of gemcitabine as a single agent
remains modest, with a median survival of approximately 6
months in randomised trials and a 12-month survival of #20%
[3,4]. A number of clinical trials are currently underway to explore
the combination of gemcitabine with either cytotoxic and/or
biological targeted compounds. So far, results have been
disappointing, showing no or little benefit compared to gemcita-
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effects associated with gemcitabine including myelosuppression.
Consequently, the development of less toxic and more efficient
treatment strategies is critical to improve the clinical management
and prognosis of these patients.
The causes of pancreatic cancer are not well understood but
attention is increasingly being directed towards the role of growth
factors. Several growth factors and their receptors are over-
expressed during the progression of pancreatic cancer, such as
epithelial growth factor (EGF), platelet-derived growth factor
(PDGF), fibroblast growth factor (FGF), and vascular endothelial
growth factor (VEGF) [7]. Deregulated expression of cytoplasmic
tyrosine kinases has also been associated with poor prognosis and
chemoresistance. In particular, gemcitabine resistance in pancreatic
cancer is often associated with high expression of focal adhesion
kinase (FAK) [8], a protein involved in metastasis; and elevated
expression and activity of Src Family Kinases (SFK), including SRC
and Lyn, have also been reported in numerous human cancer cell
lines and tumour tissues [9–11]. Moreover, increasing evidence
indicates that recruitment of inflammatory cells, especially infiltra-
tion by mast cells, facilitates the growth and spread of cancer via the
production of molecules that enhance tumour invasiveness. This
connection has been made for both exocrine (ductal adenocarcino-
mas [12]) and endocrine pancreatic cancers (islet tumour cancers
[13]). Therefore, inhibition of mast cell function may prove to be
therapeuticallyusefulinrestraining the growthof pancreatic cancer.
Masitinib is a novel tyrosine kinase inhibitor (TKI) that
specifically and selectively targets various isoforms of the c-Kit
receptor, including wild-type and those with constitutively active c-
Kit mutations in the extracellular or juxtamembrane domains,
PDGFRa, PDGFRb, Lyn, and to a lesser extent FGFR3 and the
FAK pathway [14]. Due to its activity against c-Kit and Lyn,
masitinib is particularly efficient at controlling the proliferation,
differentiation and degranulation of mast cells. Masitinib’s
antimastocyte potential is demonstrated through its efficacy in
canine mast cell tumours [15], and rheumatoid arthritis in humans
[16]. Hence, given the reported expression of PDGFRb and c-Kit
in pancreatic cancer [17], the implication of mast cells in
pancreatic cancer development, and association of FAK with
chemoresistance, it is hypothesised that masitinib may be of
therapeutic potential in this disease. This study evaluated masitinib
using in vitro and in vivo models of human pancreatic cancer, both
as a single agent and in combination with gemcitabine, with the
objective of establishing proof-of-concept. Molecular mechanisms
were investigated via gene expression profiling.
Materials and Methods
Reagents and Cancer Cell Lines
Masitinib (AB Science) was prepared from powder as a 10 or
20 mM stock solution in dimethyl sulfoxide and stored at 280uC.
Gemcitabine was obtained as a powder and dissolved in sterile
0.9% NaCl solution and stored as aliquots at 280uC. Fresh
dilutions were prepared for each experiment.
Pancreatic cancer cell lines (Mia Paca-2, Panc-1, BxPC-3 and
Capan-2) were obtained from Dr. Juan Iovanna (Inserm, France)
[18]. Cells were maintained in RPMI (BxPC-3, Capan-2) or
DMEM (Mia Paca-2, Panc-1) medium containing Glutamax-1
(Lonza), supplemented with 100 U/ml penicillin, 100 mg/ml
streptomycin, and 10% foetal calf serum (FCS) (AbCys).
Expression of tyrosine kinases was determined by RT-PCR using
Hot Star Taq (Qiagen GmbH) in a 2720 Thermal Cycler (Applied
Biosystems). All RT-PCR primer sequences used in this study are
listed in the Supporting Information (Table S1).
In Vitro Tyrosine Phosphorylation Assays
Mia Paca-2 cells (5610
6) were treated for 6 hours with
increasing concentrations of masitinib in DMEM medium with
0.5% serum. Cells were then placed on ice, washed in PBS, and
lysed in 200 ml of ice-cold HNTG buffer (50 mM HEPES pH 7,
50 mM NaF, 1 mM EGTA, 150 mM NaCl, 1% Triton X-100,
10% glycerol, and 1.5 mM MgCl2) in the presence of protease
inhibitors (Roche Applied Science) and 100 mMN a 3VO4. Proteins
(20 mg) were resolved by SDS-PAGE 10%, followed by western
blotting and immunostaining. The following primary antibodies
were used: rabbit anti-phospho-GRB2 antibody (sc-255 1:1000),
and anti-phosphotyrosine antibody (4G10 1:1000, Cell Signalling
Technology, Ozyme). Primary antibodies were detected with
1:10,000 horseradish peroxidase-conjugated anti-rabbit antibody
(Jackson Laboratory) or 1:20,000 horseradish peroxidase-conju-
gated anti-mouse antibody (Dako-France SAS). Immunoreactive
bands were detected using enhanced chemiluminescent reagents
(Pierce).
Proliferation Assays
Cytotoxicity of masitinib and gemcitabine was assessed using a
WST-1 proliferation/survival assay (Roche Diagnostics) in growth
medium containing 1% FCS. Treatment was started with the
addition of the relevant drug. For combination treatment
(masitinib plus gemcitabine), cells were first resuspended in
medium (1% FCS) containing 0, 5 or 10 mM masitinib and
incubated overnight before gemcitabine addition. After 72 hours,
WST-1 reagent was added and incubated with the cells for
4 hours before absorbance measurement at 450 nm in an EL800
Universal Microplate Reader (Bio-Tek Instruments Inc.). Media
alone was used as a blank and proliferation in the absence of drug
served as a positive control. Results are representative of three or
four experiments. The masitinib sensitisation index is the ratio of
the IC50 of gemcitabine against the IC50 of the drug combination.
In Vivo Experiments
Male Nog-SCID mice (7 weeks old) were obtained from an
internal breeding program and were housed at the animal care
unit SCEA of the Centre de Recherche en Cance ´rologie de
Marseille U891 (Marseille, France) under specific pathogen-free
conditions at 2061uC in a 12-hour light/12-hour dark cycle and
ad libitum access to food and filtered water. This study was
approved by the ethical review board at the Centre de Recherche
en Cancerolgie de Marseille and carried out in compliance with
the INSERM ethical guidelines of animal experimentation. The
animal care unit U891 (Marseille, France) is authorised by the
French Ministries of Agriculture and Research (Agreement Nu
B13-OSS-4). Mia Paca-2 cells were cultured as described above.
At day 0 (D0), mice were injected with 10
7 Mia Paca-2 cells in
200 ml PBS into the right flank. Tumours were allowed to grow for
1.5 to 4 weeks until the desired tumour size was reached
(,200 mm
3). At day 28, animals were allocated into four
treatment groups (n=7 to 8 per group), ensuring that each
group’s mean body weight and tumour volume were well
matched. Treatment was then administered for up to 4 weeks,
after which time the animals were sacrificed. Treatments consisted
of either: a) daily sterile water for the control group, b) an
intraperitoneal (i.p.) injection of 50 mg/kg gemcitabine twice a
week, c) daily gavage with 100 mg/kg masitinib, or d) combined
i.p injection of 50 mg/kg gemcitabine twice a week and daily
gavage with 100 mg/kg masitinib. Tumour size was measured
with callipers and tumour volume was estimated using the
formula: volume=(length 6 width
2)/2. The tumour growth
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of treated group)/(median tumour volume of control group).
Statistical Analysis
Relative changes in tumour volumes were compared between
treatment groups using a variance analysis (ANOVA). Normality
of relative changes in tumour volumes between day 28 and day 56
was first tested using the Shapiro-Wilk test of normality. In the
event of a positive treatment effect, treatment groups were
compared two-by-two using Tukey’s multiple comparison test. A
p-value ,0.05 was considered as significant.
Microarray Data and Pathway Analysis
Gene expression profiling of cell lines (from 2 mg RNA) was
assessed using whole-genome Affymetrix U133 Plus 2.0 human
oligonucleotide microarrays. Generation of expression matrices,
data annotation, filtering and processing have been previously
described [19]. Microarray statistics and cluster analysis were
performed by the Robust Multichip Average method in R using
Bioconductor [20] and using the Cluster and TreeView programs
[21]. Drug response signatures were generated by differential
analysis, which compared the expression profile of each treated
cell line with that of the untreated cell line by measuring the fold-
change (treated/untreated) of each probe set. The lists of
differential genes were interrogated using the Ingenuity Pathway
Analysis software (Version 5.5.1-1002; Ingenuity Systems) with
a significance threshold for the corrected p-value ,0.05.
MIAME compliant array data can be accessed at (www.ebi.ac.uk/
arrayexpress) using the accession number GSE17987.
Results
Effect of Masitinib on Pancreatic Cancer Cells In Vitro
PCR with gene-specific primers was performed to determine the
expression profile of masitinib’s targets in four human pancreatic
cancer cell lines: Mia Paca-2, Panc-1, BxPC-3 and Capan-2. C-Kit
was detectable in Panc-1 cells (described previously by Yasuda et
al. [22]) but was undetectable in all the other cell lines. PDGFRa
was expressed in BxPC-3 and Panc-1 cells while PDGFRb was
mainly expressed in Panc-1 cells. A broader profile of tyrosine
kinases revealed strong expression of the EGFR family members
ErbB1 and ErbB2, src family kinases Src and Lyn, FAK and
FGFR3, in all four cell lines (Figure 1A).
To estimate the range of masitinib concentrations necessary to
sensitise pancreatic tumour cell lines to chemotherapy, we assessed
Figure 1. Tyrosine kinase mRNA expression profile in human pancreatic cancer cell lines. (A) Messenger RNA expression of various
receptor and cytoplasmic tyrosine kinases was analysed by RT-PCR. Universal human reference total RNA was used as positive control for primers and
the ubiquitous b-glucoronidase (GUS) served as an internal control for all RT-PCR reactions. (B) Tyrosine phosphorylation of proteins in response to
masitinib. Mia Paca-2 cells (5610
6) were treated for 6 hours at 37uC with various concentrations of masitinib. Total cell lysates were prepared and
tyrosine phosphorylation was analysed by western blot with antibodies against phosphotyrosine (anti-pTyr). Anti-GRB2 WB demonstrates
comparable loading of proteins. MW=molecular weight.
doi:10.1371/journal.pone.0009430.g001
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by western blot analysis in cell lysates. Figure 1B shows a strong
pattern of protein tyrosine phosphorylation at baseline in Mia
Paca-2 cells. Treatment with masitinib clearly inhibited tyrosine
phosphorylation at 1 mM and beyond, demonstrating that
masitinib is active at these concentrations. The control protein
GRB2 remained unchanged under all treatment conditions.
Similar results were obtained with the three other pancreatic
tumour cell lines (data not shown). Based on these results, a
masitinib concentration of up to 10 mM was considered appro-
priate to study its effect on cell proliferation.
The antiproliferative activity of masitinib or gemcitabine in
monotherapy was assessed by WST-1 assays (Figures 2A and B).
Masitinib did not significantly affect the growth of the tested
cell lines, with an IC50 of 5 to 10 mM. Figure 2B shows
that gemcitabine inhibits cell lines BxPC-3 and Capan-2 with an
IC50 of 2–20 mM, while Mia Paca-2 and Panc-1 cells show
resistance (IC50.2.5 mM) as previously reported [18]. Masitinib’s
potential to enhance gemcitabine cytotoxicity was assessed by
pre-treating cell lines with masitinib overnight then exposing them
to different doses of gemcitabine and recording the IC50
concentrations. Table 1 summarises the IC50 of gemcitabine in
the absence or presence of 5 and 10 mM masitinib. Mia Paca-2
cells, pre-treated with 5 and 10 mM masitinib, were significantly
sensitised to gemcitabine, as evidenced by the substantial
reductions (.400-fold reduction) in gemcitabine IC50 (Figure 2C;
Table 1). Panc-1 cells were moderately sensitised (10-fold
reduction) and no synergy was observed in the gemcitabine-
sensitive cell lines Capan-2 and BxPC-3 (Table 1). The treatment’s
antiproliferative action was confirmed via microscopic observa-
tion, which clearly revealed cells to be dying rather than being
arrested in the cell cycle (data not shown). These results suggest
that pre-treatment with masitinib can restore cellular responsive-
ness to gemcitabine.
Figure 2. Masitinib resensitisation of resistant pancreatic tumour cell lines Mia Paca-2 and Panc-1 to gemcitabine. Sensitivity of
pancreatic tumour cell lines to masitinib or gemcitabine as single agents, or in combination, was assessed using WST-1 proliferation assays. Four cell
lines were tested for their sensitivity to masitinib (A) or gemcitabine (B). (C) Combination treatment of masitinib plus gemcitabine tested on
gemcitabine-resistant Mia Paca-2 cells. (D) Sensitivity of resistant Mia Paca-2 cells to various tyrosine kinase inhibitors alone (top) or in combination
with gemcitabine (bottom) was analysed in WST-1 proliferation assays. TKI=tyrosine kinase inhibitor.
doi:10.1371/journal.pone.0009430.g002
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to Sensitise Gemcitabine-Resistant Pancreatic Cancer
Cells
Similar TKI plus gemcitabine combination experiments to
those described above were performed with gemcitabine-resistant
Mia Paca-2 cells to compare masitinib with imatinib (Gleevec,
STI-571; Novartis), a TKI targeting ABL, PDGFR, and c-Kit);
and dasatinib (Sprycel, Bristol-Myers Squibb), a TKI targeting
SRC, ABL, PDGFR, and c-Kit. Mia Paca-2 cell proliferation
was not inhibited by imatinib alone (10 mM), whereas it was
partially inhibited in the presence of low concentrations of
the SRC inhibitor dasatinib (.0.1 mM); albeit with ,50% of
the cells remaining resistant (Figure 2D). Pre-incubation of cells
with 10 mM of imatinib or dasatinib did not result in an
increased response of Mia Paca-2 cells to gemcitabine as
compared to masitinib (Figure 2D). Therefore, only masitinib
was able to restore sensitivity to gemcitabine in Mia Paca-2
cells.
Effect of Masitinib on Human Pancreatic Cancer In Vivo in
a Nog-SCID Mouse Model
Preliminary experiments showed the optimal doses to use
in this model (in terms of the combination’s response and risk)
were masitinib at 100 mg/kg/day by gavage and gemcitabine
at 50 mg/kg twice weekly by i.p. injection (data not shown).
Tumours of the desired size (200 mm
3) were obtained 28 days
following Mia Paca-2 cell injection. The tumour size was
monitored every 7 days until day 56, after which time the
animals were sacrificed. Figure 3 shows stabilisation of tumour
growth between day 35 and 49 in mice treated with gemcitabine
or gemcitabine plus masitinib. Tumour response for each
treatment group is reported in Table 2. The antitumour
effect continued until day 56 (28 days of treatment) with better
control of tumour growth evident in mice treated with the
gemcitabine plus masitinib combination, as compared to the
masitinib monotherapy or the control groups. Overall response
analysis at day 56 defined a responder as having a smaller
tumour volume than the lower range limit of the control group
(i.e. 711 mm
3). Following 28 days of treatment, 3/7 mice (43%)
treated with masitinib alone were responders, with 6/8 mice
(75%) responding in both the gemcitabine monotherapy and
masitinib plus gemcitabine groups. Median tumour volumes were
significantly reduced in the gemcitabine monotherapy and
masitinib plus gemcitabine groups relative to control (p,0.05
Tukey’s multiple comparison test). Although statistical signifi-
cance was not demonstrated (p.0.05), the combination of
masitinib plus gemcitabine appeared more potent than gemcita-
bine alone, with this observed trend being consistent over two
separate experiments.
Gene Expression Signature in Response to Masitinib Plus
Gemcitabine Treatment
To better understand the molecular mechanisms underlying the
observed masitinib chemosensitisation, Mia PaCa-2 cells under
various treatment regimens (untreated, masitinib monotherapy,
gemcitabine monotherapy, or masitinib plus gemcitabine in
combination), were profiled using DNA microarrays. Whole-
genome clustering of the four cell samples sorted them into two
opposite clusters (Figure 4A). The two treatment regimens with
gemcitabine clustered together (left cluster), whereas cells treated
with masitinib alone clustered with the untreated cells (right
cluster). This result suggests that changes of gene expression in
response to masitinib treatment are less numerous than those
associated with gemcitabine chemotherapy, which is to be
expected as masitinib is a more targeted agent. This was confirmed
by the differential analysis of the expression profile (Figure 4B).
Using a fold-change threshold of 2 (up-regulation) and 2 (down-
regulation), we identified 971 deregulated genes after combined
masitinib plus gemcitabine treatment (845 up- and 126 down-
regulated); 1161 deregulated genes after gemcitabine monother-
apy (1048 up- and 113 down-regulated); and only 354 deregulated
genes after masitinib monotherapy (325 up- and 29 down-
regulated). Results are displayed in Figure 4C as a colour-coded
Figure 3. In vivo anti-tumour activity of masitinib in a Nog-SCID
mouse model of human pancreatic cancer. Mia Paca-2 tumour
cells (10
7) were injected into the flank of Nog-SCID mice. Treatment was
initiated 28 days after tumour cell injection. The different groups were
treated with either: twice weekly injections of gemcitabine (i.p. 50 mg/
kg), daily oral masitinib (100 mg/kg), water (control), or combined daily
oral masitinib (100 mg/kg) and twice weekly injections of gemcitabine.
Mice were treated for 28 days.
doi:10.1371/journal.pone.0009430.g003
Table 1. IC50 concentrations (mM) of various masitinib and/or gemcitabine treatment regimens in different pancreatic cell lines.
Masitinib Gemcitabine
Gemcitabine plus
5 mM masitinib
Gemcitabine plus
10 mM masitinib
Sensitisation
Index
*
BxPC-3 5–10 10 10 10 1
Capan-2 5–10 2 2 NA 1
Mia Paca-2 5–10 .10 1.5 0.025 400
Panc-1 5–10 .10 8 1 10
*Sensitisation Index is defined as the IC50 ratio of gemcitabine alone against the gemcitabine plus masitinib combination. NA=Not available.
doi:10.1371/journal.pone.0009430.t001
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expression signatures were characterised via pathway analysis
using Ingenuity software (see Supporting Information; Table S2).
From the 971 genes deregulated after combined masitinib plus
gemcitabine treatment, 142 (100 up- and 42 down-regulated
genes, listed in Supporting Information; Tables S3A and S3B,
Figure 4. Gene expression analysis in response to masitinib, gemcitabine or combined treatment. Gene expression analysis was
performed following 24 hours of treatment with masitinib 5 mM, gemcitabine 1 mM, or masitinib plus gemcitabine. (A) Hierarchical clustering of
treated and untreated Mia Paca-2 cell line and 13,612 probe sets with variation expression levels across all samples. Each row represents a probe set
and each column a sample. The expression level of each probe set, relative to its median abundance across the samples, is depicted according to the
colour scale shown at the bottom. Red and green indicate expression levels above and below the median, respectively. The magnitude of deviation is
represented by the colour saturation. The dendrogram of samples (on top of matrix) represents overall similarities in expression profiles. The
correlation coefficient (r) of linked samples is indicated. (B) Venn diagram of genes differentially expressed after each treatment. Up: genes up-
regulated (Fold Change: FC$2); down: genes down-regulated (FC#22). The coloured circles indicate deregulated genes (specific or not to the
treatment), whereas the coloured squares indicate the genes deregulated in a treatment-specific manner. (C) Hierarchical clustering of treated cell
lines and 1412 genes deregulated in response to treatment in at least one condition. Legend is similar to (A). Before clustering, the expression profile
of each treated cell line was divided by that of the control cells. Data are not median-centred.
doi:10.1371/journal.pone.0009430.g004
Table 2. Effect of masitinib plus gemcitabine on Mia Paca-2 pancreatic tumours in Nog-SCID mice, following 28 days of treatment.
Treatment group Response rate Tumour volume (mm
3) Relative change in volume (%)
Median Range Mean6SD Range
Control 0/7 (0%) 1023 711–1422 5.462.3 2.8–9.0
Masitinib (100 mg/kg) 3/7 (43%) 865 450–1543 4.861.4 2.6–6.6
Gemcitabine (50 mg/kg) 6/8 (75%) 662* 353–1317 2.161.1 0.7–3.6
Masitinib+Gemcitabine 6/8 (75%) 526* 166–1190 2.461.8 0.0–5.3
*p-value,0.05 versus control using Tukey’s multiple comparison test. Responders are defined as having a smaller tumour volume than the lower range limit of the
control group (i.e. 711 mm
3). Relative change in tumour volume was measured from day 28 to day 56.
doi:10.1371/journal.pone.0009430.t002
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bine or masitinib monotherapies, 818 and 201 genes were
deregulated, respectively (Figure 4B). When considering these
specific combination-regulated genes, no pathway was found to be
significantly over-represented among the up-regulated genes (see
Supporting Information; Table S2). Among the down-regulated
genes, one oncogenic pathway emerged as the most significantly
over represented, the Wnt/b-catenin signalling (p,0.001). Three
other pathways which were altered to a lesser extent included:
ERK/MAPK signalling, CDK5 signalling, and PI3K/AKT
signalling (p=0.016, 0.025, 0.039, respectively).
Discussion
The pancreatic tumour cell lines used in this study were selected
for their different sensitivities to standard gemcitabine chemother-
apy. BxPC-3 and Capan-2 cell growth was efficiently inhibited by
gemcitabine, while Mia Paca-2 and Panc-1 cells were resistant.
None of the cell lines, including those expressing c-Kit and
PDGFRa or b, showed sensitivity to masitinib monotherapy. Of
the tyrosine kinases strongly expressed in all four cell lines,
masitinib inhibits Lyn (IC50 of 400 nM), and to a lesser extent
FGFR3 (IC50 2.5 mM) [14]. This suggests that proliferation of
these cell lines does not depend significantly upon the major kinase
targets of masitinib. The mechanisms leading to gemcitabine
resistance in pancreatic cancer are often associated with FAK and
SFK. However, in accordance with masitinib’s pharmacological
profile [14], the observed resensitisation activity of masitinib is not
due to direct inhibition of these targets, but more likely results
from a complex interplay of factors. Indeed, preliminary data
show that despite masitinib being inactive against purified FAK
[14], 1 mM of masitinib is capable of reducing FAK phosphor-
ylation in a cell-based assay (our unpublished results). Another
possible mechanism of chemoresistance is impaired drug delivery
[23]. Olive et al. have demonstrated that the Hedgehog (Hh)
signalling pathway has a role in the delivery of chemotherapeutic
agents in a mouse model of pancreatic ductal carcinoma [24].
Therefore, additional as yet uncharacterised targets of masitinib
may be involved in the molecular mechanism underlying its
synergy with gemcitabine. Using a kinome screening approach, J.
Iovanna’s laboratory has identified kinases involved in the
resistance of pancreatic cancer cells to gemcitabine [18]. Among
them MAPKAP1/RSK2/ISPK, MAK, PAK4, ADRBK1/GRK2
and PIK3CG were the most active, while SRC inhibition did not
enhance the response of cells to gemcitabine, similar to our results
with dasatinib. Future work will test the activity of masitinib on
these kinases.
Analysis of the transcriptome of gemcitabine-resistant Mia
Paca-2 cells revealed differences in up- and down-regulated genes
unique to the masitinib plus gemcitabine combination. The most
significantly altered pathway involved genes associated with Wnt/
b-catenin signalling, a pathway that regulates cell proliferation,
differentiation and stem cell renewal [25]. This pathway is
involved in pancreatic development and re-activation of this
signalling system has been implicated in pancreatic carcinoma
with reported nuclear localisation of the downstream effector b-
catenin [25]. Down-regulation of genes involved in this signalling
pathway by a combination of masitinib plus gemcitabine, may
therefore contribute to accelerated death in Mia Paca-2 cells as
compared to gemcitabine monotherapy. Hence, it will be
important to determine changes in activation, stabilisation and
subcellular localisation of b-catenin in Mia Paca-2 cells following
treatment with the drug combination. Other down-regulated
kinase-associated pathways warranting further investigation in-
cluded ERK/MAPK signalling, CDK5 signalling and PI3K/AKT
signalling.
The efficacy of TKI therapy has been previously evaluated in an
orthotopic nude mouse model of human pancreatic cancer, both
as monotherapy and as combination therapy with gemcitabine.
The inhibitors investigated were the BCR-ABL/c-Kit/PDGFRb
inhibitor imatinib (Glivec, STI571) [26], the EGFR/VEGFR/
PDGFR inhibitor AEE-788 [27], and the SFK/ABL inhibitor
dasatinib (BMS-354825) [28]. Those preclinical studies demon-
strated increased efficiency of gemcitabine when used in
combination with kinase inhibitors, resulting mainly in extended
survival and inhibition of metastasis. This supports the general
interest of using TKIs in combination therapy with gemcitabine.
However, under the conditions of this in vitro study we were unable
to re-sensitise resistant Mia Paca-2 cells to gemcitabine when used
in combination with dasatinib or imatinib, in contrast to our
findings for masitinib (Figure 2D). One interpretation of these
results is that the combination of masitinib plus gemcitabine might
be more potent in human pancreatic cancer than other TKIs,
particularly in cases of cancers that relapse after a first line of
treatment. Additionally, many of these inhibitors, including
dasatinib and imatinib, have been associated with cardiotoxicity
[29]. Conversely, the accumulated clinical experience of masitinib
(.485 patients exposed) has revealed no evidence of cardiotoxicity
in humans; consistent with its known low cardiac risk pharmaco-
logical profile [14].
In summary, combined treatment with masitinib plus gemcita-
bine resulted in resensitisation of resistant pancreatic cell lines in
vitro. This chemosensitisation may allow lower concentrations of
gemcitabine to be used, thereby reducing the risk of toxicity or
increasing the available efficacy at standard gemcitabine doses.
Such synergy was not observed with BxPC-3 and Capan-2 cells,
possibly because of the already strong cytotoxicity of gemcitabine
on these cell lines. In this study, masitinib was used at 5 and
10 mM over a 72-hour incubation time. These conditions do not
necessarily reflect those to be used in the clinical setting, but rather
demonstrate the concept. Pharmacokinetic data from previous
clinical studies show that at typical masitinib doses (#12 mg/kg/
day), concentrations of 2 mM are achievable in vivo. However,
repetition of the proliferation assays at 1 and 2 mM failed to
reproduce the observed resensitisation (data not shown). For this
reason, the in vivo antiproliferative activity of masitinib was
explored in a Nog-SCID mouse model of human pancreatic
cancer. As expected, gemcitabine monotherapy efficiently reduced
tumour growth compared to the control, while masitinib
monotherapy only weakly inhibited tumour growth. The combi-
nation of masitinib plus gemcitabine also reduced tumour growth
and showed a possible (statistically non-significant) improvement
in tumour inhibition as compared to gemcitabine monotherapy.
These results tentatively confirm the hypothesis that masitinib can
enhance the antiproliferative activity of gemcitabine in vivo and
provide supporting evidence for the in vitro assay results. However,
further confirmation that these proof-of-concept results are of
clinical relevance is evidenced by a recent phase 2 study (the
results of which postdate the data reported here), in which patients
with advanced pancreatic cancer who received a combination of
masitinib (9 mg/kg/day) plus gemcitabine showed significantly
improved median time-to-progression compared to patients
treated with gemcitabine alone [30].
The preclinical data reported here establish the proof-of-
concept that masitinib can reverse resistance to chemotherapy in
pancreatic tumour cell lines. Masitinib used in combination with
gemcitabine has promising potential in the treatment of pancreatic
Gemcitabine Plus Masitinib
PLoS ONE | www.plosone.org 7 March 2010 | Volume 5 | Issue 3 | e9430cancer, particularly in cases where the tumour has become
refractory to conventional chemotherapy.
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